Clinical trial
A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV
NCT07822477 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV
- Lead sponsor
- ViiV Healthcare
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 6, 2026
- Completion date
- May 9, 2029
- Enrollment
- 160 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.